Poland

Reimbursed Care Access

Poland has a restrictive national drug-control framework that places classic psychedelics (psilocybin, DMT, mescaline, MDMA and many tryptamines/2C-derivatives) in controlled lists, with authorised medical use limited to clinical research or tightly regulated exceptions. Esketamine (Spravato) is the single psychedelic-derived medicine implemented into a reimbursed drug‑program (B.147) for treatment‑resistant depression; ketamine is legally available for anaesthesia and appears in private/off‑label psychiatric services but is not reimbursed for routine antidepressant indications. Most other psychedelics owe possible access only to approved clinical trials or are otherwise prohibited outside research/authorised use under the Act on Counteracting Drug Addiction and the Minister of Health regulation.